Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label first-in-human study of MDX2004 in advanced solid tumors
MOH_2023-08-02_012801Phase 2Recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDX2004 in Nonhematologic neoplasms (4 arms), sponsored by ModeX Therapeutics. Primary endpoint: Incidence and severity of adverse events and serious adverse events. Started Aug 2025; status: recruiting.
02
Drugs
MDX2004
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2023-08-02_012801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-02_012801.